BeOne Medicines AG (BEIGF)
OTCMKTS · Delayed Price · Currency is USD
23.75
0.00 (0.00%)
At close: Mar 2, 2026
BeOne Medicines AG Employees
BeOne Medicines AG had 12,000 employees as of December 31, 2025. The number of employees increased by 1,000 or 9.09% compared to the previous year.
Employees
12,000
Change
1,000
Growth
9.09%
Revenue / Employee
$445,253
Profits / Employee
$23,911
Market Cap
33.41B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 12,000 | 1,000 | 9.09% | 12,000 | 0 |
| Sep 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Jun 30, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Mar 31, 2025 | 11,000 | 1,000 | 10.00% | 11,000 | 0 |
| Dec 31, 2024 | 11,000 | 400 | 3.77% | 11,000 | 0 |
| Jun 30, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Mar 31, 2024 | 10,000 | 600 | 6.38% | 10,000 | 0 |
| Dec 31, 2023 | 10,600 | 1,600 | 17.78% | 10,600 | 0 |
| Mar 31, 2023 | 9,400 | 1,100 | 13.25% | 9,400 | 0 |
| Dec 31, 2022 | 9,000 | 1,000 | 12.50% | 9,000 | 0 |
| Sep 30, 2022 | 9,000 | 1,400 | 18.42% | 9,000 | 0 |
| Mar 31, 2022 | 8,300 | 2,900 | 53.70% | 8,300 | 0 |
| Dec 31, 2021 | 8,000 | 2,700 | 50.94% | 8,000 | 0 |
| Sep 30, 2021 | 7,600 | 3,000 | 65.22% | 7,600 | 0 |
| Mar 31, 2021 | 5,400 | 1,800 | 50.00% | 5,400 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Silence Therapeutics | 116 |
| Vaxart | 105 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
| ZIVO Bioscience | 7 |
| Vicapsys Life Sciences | 2 |
| Cell Source | 1 |
BeOne Medicines AG News
- 11 months ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 1 year ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire